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Unraveling the pathogenesis of a complex disease is daunt-
ing. Variation in multiple genes and multiple environ-
mental factors could be at play, as could variation in the
interactions of these risk factors with each other. Lest
you despair, Cadwell et al. prove that it is possible to reveal
features of the disease process through a careful set of
experiments with good controls. The researchers previ-
ously reported a mouse model of Crohn disease that is
hypomorphic for Atg16L1, an autophagy gene that was
pulled out of a genome-wide association study for Crohn
disease. When these mice were rederived in a different
animal facility with higher containment procedures,
however, the Crohn-like phenotype was not evident. The
group tracked this phenotype difference down to a murine
norovirus strain that contributes to the intestinal pheno-
type through establishment of a persistent infection.
Once this infection is established, the mice have increased
susceptibility to additional environmental insult in the
form of dextran sodium sulfate (DSS), a toxin that injures
the intestine. Altogether, Atg16L1 hypomorphic mice
that are infected with the norovirus and later given DSS
exhibit several pathological features reminiscent of human
Crohn disease. However, this is not the full story; the
timing of the viral infection and DSS administration
must be spaced if one is to see the intestinal damage, which
also requires the presence of commensal bacteria in the
gut. Treating the Atg16L1 hypomorphic mice with broad-
spectrum antibiotics to kill these bacteria prevents the
damage induced by DSS. Truly, Crohn disease is complex,
but this carefully executed set of experiments ties together
at least one genetic risk factor with three separate environ-
mental contributions to the disease process.
Cadwell et al. Virus-plus-susceptibility gene interaction
determines Crohn’s disease gene Atg16L1 phenotypes in
intestine. Cell, 141:1135–1145.
Convergent Evolution of the Human X and Chicken Z
Chromosomes through Gene Addition
The mammalian X and Y chromosomes are thought to
have diverged from a pair of ancestral autosomes. Much
of this divergence has been attributed to the degeneration
of the Y chromosome, whereas the X chromosome has
been assumed to be evolutionarily fairly stable. The same
basic process is thought to hold true in birds, with the Z
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The Americand the W degenerating from there. A recent paper by
Bellott et al. challenges the assumption of the static
Z and X chromosomes. They use the completed chicken
Z and human X chromosome sequences to show that,
although these chromosomes share several features, they
evolved independently from different parts of the ancestral
vertebrate genome, meaning that their similarities arose
through convergent evolution. The similarities include
the acquisition of hundreds of genes but a paradoxically
low gene density that is due not to loss of other genes
but, rather, to expansion of intergenic regions. Most of
the acquired genes are members of multigene families
that are expressed in the testis, thereby biasing the gene
content toward those involved in male reproduction.
On the Z chromosome, this includes an 11 Mb tandem
array of testis-expressed genes that encompasses almost
1% of the total chicken genome. This work puts a dent
in the long-held notion that it is only the sex-specific chro-
mosomes that have undergone drastic changes during
their evolution.
Bellott et al. Convergent evolution of chicken Z and
human X chromosomes by expansion and gene acquisition.
Nature Advance Online Publication, published 7/11/10,
doi:10.1038/nature09172.
Mutation-Guided Cancer Therapy
Defects in a pathway for DNA double-strand break repair
are the underlying cause of cancer in people who inherit
mutations in BRCA1 or BRCA2. A recent set of clinical trials
indicates that our understanding of this defect might
improve treatment for cancer patients with hereditary
breast or ovarian cancer. Tumorigenesis in these individ-
uals involves loss of the second, wild-type allele of the rele-
vant gene, thereby rendering cells incapable of using this
particular DNA repair pathway. Because these tumors
must rely on the remaining DNA repair pathways, the cells
are susceptible to inhibitors of a DNA repair pathway for
single-strand breaks, at least in vitro. Two recent papers
report the clinical efficacy of such an inhibitor called
olaparib, which targets poly(ADP-ribose) polymerase
(PARP). In phase 2 trials of olaparib for patients with
advanced breast or ovarian cancer due to mutations in
BRCA1 or BRCA2, the tumors in up to 33% and 41% of
patients with ovarian and breast cancer, respectively, re-
sponded to treatment. If this drug is proven to be effective
in a phase 3 trial, there will come a day when cancerta, GA 30322, USA
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patients will be grouped for treatment on the basis of the
underlying genetic defect that caused their cancer.
Tutt et al. Oral poly(ADP-ribose) polymerase inhibitor
olaparib in patients with BRCA1 or BRCA2 mutations and
advanced breast cancer: A proof-of-concept trial. The
Lancet, published online 7/6/10, doi:10.1016/S0140-6736
(10)60892-6.
Audeh et al. Oral poly(ADP-ribose) polymerase inhibitor
olaparib in patients with BRCA1 or BRCA2 mutations and
recurrent ovarian cancer: A proof-of-concept trial. The Lancet,
published online 7/6/10, doi:10.1016/S0140-6736(10)
60893-8.
Direct-to-Consumer Research
The growth of the direct-to-consumer personal genetics
testing industry means that there are large samples of
people who are interested in genetics and who have
submitted a DNA sample for genotyping. What is the
potential for these samples to be used for research? In a
recent article in PLOS Genetics, Eriksson et al. illustrate
the power of these samples in a genome-wide association
study for 22 traits, using data collected through 23andMe.
In their sample of people who ordered personal genome
scans (and who consented to the use of their information
for research), they replicated associations for pigmentation
traits and identified novel associations for other personal
traits, including the ability to smell asparagus in urine
and the tendency to sneeze when entering bright light.
Although powerful, the use of this type of sample is not
straightforward. The accompanying editorial describes
the complicated process by which the editors at PLOS
Genetics assessed issues of consent, ethics, and data access
related to this paper, including a debate over whether or
not this constituted ‘‘human subjects research.’’ As an
interesting aside, the Eriksson et al paper touched on an
aspect of personal genome scans that could have implica-
tions for the use of this type of scan in disease-risk assess-
ment. They found that participants’ answers to personal
survey questions could be strongly biased if they were pre-
sented with their own genotype data and interpretation
before they answered a question about that trait. Could
this mean that genetic determinism trumps the benefit166 The American Journal of Human Genetics 87, 165–167, August 1of patients being given risk information? This seems like
an area ripe for further exploration.
Eriksson et al. Wed-based participant-driven studies
yield novel genetic associations for common traits. PLOS
Genetics, published online 6/24/10, doi:10.1371/journal.
pgen.1000993.
Gibson and Copenhaver. Consent and internet-enabled
human genomics. PLOS Genetics, published online 6/24/10,
doi:10.1371/journal.pgen.1000965.
Man versus Parasite
The classic example of heterozygote advantage is the sickle
cell mutation, which confers resistance to malaria in the
heterozygous state and causes sickle cell disease in the
homozygous state. Although it is unlikely that this type
of selective force is unique to malaria, other examples of
heterozygote advantage have been hard to pin down.
Recent work by Genovese et al. suggest that Trypanosoma
brucei, the parasite that causes sleeping sickness, may
have selected for another detrimental mutation in
humans. The authors were looking for genetic variation
that might contribute to the high rate of kidney disease
in African Americans and found an association with chro-
mosome 22 that was originally attributed to MYH9.
Further analysis of the region indicated that the strongest
association was actually with APOL1, a gene that encodes
the apolipoprotein L-1, a protein that has anti-trypanoso-
mal activity. The authors find evidence of selection for
the kidney disease risk allele in African populations and
also demonstrate that plasma samples from people with
the risk allele are better able to lyse T. brucei rhodesiense.
Similar to the malaria story, the protective effect against
trypanosomes is dominant, whereas the association with
kidney disease is recessive. Thus, although the APOL1
allele might have protected some of our ancestors from
sleeping sickness, it is now found in more than 30% of
African American chromosomes and couldmake a substan-
tial contribution to renal disease in this population.
Genovese et al. Association of trypanolytic ApoL1
variants with kidney disease in African-Americans. Science
Express, published online 7/15/10, doi:10.1126/science.
1193032.This Month in Our Sister JournalsA 19p13.13 Microdeletion or Microduplication
Syndrome
The increased use of whole-genome comparative
genomic hybridization arrays for assessment of individ-
uals with developmental delay has allowed us to recog-
nize several novel microdeletion or microduplication
syndromes. Dolan et al. add to this number with
a description of individuals with deletions or duplica-
tions of chromosome 19p13.13. Four individuals withoverlapping but unique de novo deletions in this region
share three abnormalities in addition to developmental
delay. These are: overgrowth, particularly macrocephaly
with frontal bossing; eye abnormalities, including stra-
bismus and optic nerve atrophy; and gastrointestinal
symptoms, such as diarrhea, vomiting, and abdominal
pain. Similar organ systems are affected in an individual
with a duplication in this region. This child also had
ophthalmologic problems and gastrointestinal issues3, 2010
but was small for his age and had microcephaly. Three
individuals with deletions in this region were previously
tested for NSD1 mutations to rule out Sotos syndrome.
Because of this, the authors suggest that the 19p13.13
microdeletion syndrome might be considered in a childThe Americsuspected of having Sotos syndrome when NSD1 testing
is negative.
Dolan et al. Anovelmicrodeletion/microduplication syndrome
of 19p13.13. Genetics in Medicine, doi:10.1097/GIM.
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